Compare Nutrien Ltd (NTR) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutrien Ltd vs Novartis AG — how do they compare? Nutrien Ltd trades at $66.8 (market cap $31.67B), while Novartis AG trades at $153.88 (market cap $290.25B). The key difference: Novartis AG is far larger — about 9.2× Nutrien Ltd's market cap, and Nutrien Ltd pays the higher dividend (3.3%). Which is the better fit depends on your goals.
| NTR | NVS | |
|---|---|---|
Market Cap | $31.67B | $290.25B |
Sector | Basic Materials | Health |
52-Week High | $83.94 | $168.62 |
52-Week Low | $53.64 | $113.50 |
Enterprise Value | $44.84B | $330.27B |
Dividend Yield | 3.3% | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutrien (NTR) trades at $66.84, down 0.65% with neutral technical signals. The company shows improving fundamentals with Q1 2026 earnings beat and projected revenue growth to $27.8B in 2026. Valuation appears reasonable with P/E of 13.58 and P/S of 1.16. Recent institutional buying activity and a $0.55 dividend payment scheduled for July 2026 provide additional investor appeal.
The outlook remains positive with strong analyst consensus (60.6% buy ratings) and $77.67 price target suggesting 16% upside. Key risks include volatile input costs and fertilizer market dynamics. The combination of reasonable valuation, earnings momentum, and institutional support positions NTR favorably for long-term investors despite near-term market volatility.
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
